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ABSTRACT
Arsenic exposure, through various routes, is associated with the development of
cancer of the skin, lung, liver, kidney, and bladder. Treatment of cells in culture with
trivalent arsenicals has been shown to increase reactive oxygen species (ROS).

In

particular, monomethylarsonous acid (MMAIII), a trivalent metabolite of arsenite, is
highly cytotoxic and possibly carcinogenic. Three trivalent arsenicals; arsenite, arsenic
trioxide (ATO), and MMAIII, are also known inhibitors of the selenoprotein thioredoxin
reductase (TrxR). Selenium, an essential micronutrient in mammals, is needed in the
form of selenocysteine for activity of this enzyme and other selenoproteins. TrxR is part
of a key component of the cell’s ability to defend against ROS. It has been speculated
that TrxR is also involved directly in selenium metabolism, but this has yet to be
demonstrated in vivo. The promoter region of the gene encoding the cytosolic TrxR
(TrxR1) also contains an antioxidant responsive element (ARE). The ARE is activated
by the transcription factor, Nrf2, which is governed by the Nrf2/Keap1 response, and can
be triggered by certain oxidants.
ATO and arsenite both inhibited incorporation of selenium into selenoproteins.
Auranofin, a gold chemotherapeutic inhibitor of TrxR1, also inhibited selenoprotein
synthesis.

These results seem to support the hypothesis that TrxR1 is needed for

selenoprotein synthesis. However, siRNA mediated reduction of TrxR1 did not block
incorporation of selenium into selenoproteins. It is likely that ATO and auranofin are
forming As-Se and Au-Se complexes, respectively.
We also found that exposure of primary lung fibroblasts (WI-38) to MMAIII led to
increased synthesis of TrxR1.

This increase was dependent on the activation of
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transcription of the TrxR1 gene, specifically mediated through the ARE element. These
results indicate exposure to MMAIII induces the Nrf2 response.
The results obtained in these studies aid in both our understanding of the
carcinogenic potential of arsenic as well as give new insight into the mechanism of action
of emerging cancer drugs.
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CHAPTER ONE: LITERATURE REVIEW
Selenium metabolism and selenoprotein synthesis

Selenium is an essential trace element for mammals. It was first discovered by
the Swedish chemist Berzelius, and named after Selene, the goddess of the moon. At first
selenium was thought to be a toxin, but it is now recognized for it’s role in a family of
proteins. The form of selenium present in these proteins is selenocysteine, and this has
been coined as the 21st amino acid.
Selenoproteins are found in bacteria, archaea, and eukarya, but not in all species
of each grouping. Selenium metabolism slightly differs between the prokaryotic and
eukaryotic worlds, however the focus here will be the eukaryotic, in particular mammals.
There are 25 known selenoproteins in humans (Kryukov, Castellano et al. 2003).

The

first protein to be identified to have selenocysteine at its catalytic site was glutathione
peroxidase (Gpx) (Forstrom, Zakowski et al. 1978). At least three targeted gene deletions
of the selenoproteins, thioredoxin reductase 1 (TrxR1), TrxR2, and glutathione
peroxidase 4 (GPx4), are embryonic lethal (Imai, Hirao et al. 2003; Nonn, Williams et al.
2003; Jakupoglu, Przemeck et al. 2005). Also a deletion for the gene encoding for
Selenocysteyl-tRNA[Ser]Sec(SectRNA[Ser]Sec),

the

SectRNA[Ser]Sec,

results

in

early

embryonic lethality (Bosl, Takaku et al. 1997). These studies emphasize the importance
of selenoproteins in development.
Only a few groups of selenoproteins have been functionally characterized. The
function of most selenoproteins has yet to be elucidated. Of the selenoproteins that have
been classified they comprise of diverse functions, mainly anabolic metabolism and
antioxidant defense.

The one thing that they have in common is at least one
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selenocysteine (Sec) residue in every selenoprotein. Selenoprotein synthesis is unlike
traditional protein synthesis (Figure 1). This is primarily a result Sec being encoded by
what is usually a stop codon, UGA, which was first discovered in the protein GPx
(Chambers, Frampton et al. 1986).
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Figure 1. An overview of selenium metabolism in mammals
Pictured above is an overview of selenium metabolism in mammals. Selenide is utilized
by SPS2 to produce selenophosphate. This and the phosphoseryl-tRNA[Ser]Sec is used by
soluble liver antigen (SLA) to generate the Sec-tRNA[Ser]Sec. Figure adapted from (Papp,
Lu et al. 2007).
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Selenoprotein synthesis is a complex process involving a myriad of factors (Figure
1). The first of these is the unique tRNA. Sec-tRNA[Ser]Sec is the only tRNA known to
govern expression of an entire class of proteins. Read-through of UGA codon requires a
seryl-tRNA that is converted to SectRNA[Ser]Sec.

This tRNA only recognizes UGA

codons coding for Sec, no other stop codons or serine codons. The seryl-tRNA must be
processed by several steps for the finished product of SectRNA[Ser]Sec. PhosphoseryltRNA[Ser]Sec kinase (PSTK) has been found to phosphorylate seryl- tRNA[Ser]Sec and is
essential in the formation of SectRNA[Ser]Sec in eukaryotes (Carlson, Xu et al. 2004). The
protein soluble liver antigen (SLA) was recently identified as the mammalian homolog of
SelA.

This is the enzyme that dephosphorylates O-phosphoseryl -tRNA[Ser]Sec and

accepts the selenium donor to make Sec-tRNA[Ser]Sec (Xu, Carlson et al. 2006).
Another protein involved in selenium metabolism is selenophosphate synthetase 2
(SPS). Humans have two SPS proteins, where prokaryotes only have one. SPS2 is also a
selenoprotein (Guimaraes, Peterson et al. 1996). This protein catalyzes the formation of
selenophosphate from selenide, and is ATP dependent. It has also been proposed that the
selenophosphate produced by SPS2 is the selenium donor utilized by SLA to produce
SectRNA[Ser]Sec (Xu, Carlson et al. 2006) .
The next element that is required for selenoprotein synthesis is the selenocysteine
insertion sequence (SECIS). In eukaryotes the stem looped SECIS element is in the 3’
untranslated region, and may be kilobases away from the UGA codon which encodes for
Sec (Berry, Banu et al. 1993).

This structure does share similar sequences among

selenoproteins, but it does have a highly conserved secondary structure, the stem loop,
that is necessary for Sec insertion (Krol 2002). A single SECIS element is all that is
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needed in selenoprotein synthesis, with the exception of Selenoprotein P (SelP), which
contains 10 UGA codons coding for Sec (Castellano, Lobanov et al. 2005).
Efficient insertion of Sec also requires several other proteins, one of these being
SECIS binding protein2 (SBP2). To determine that SBP2 was essential to selenoprotein
synthesis cell lysates were depleted of SBP2 and this resulted in an abolishment of
selenoprotein synthesis. When SBP2 was added selenoprotein synthesis was restored
(Copeland, Fletcher et al. 2000). SBP2 binds to the SECIS element (Lescure, Allmang et
al. 2002) and also interacts with the ribosome through the 28S rRNA, suggesting that
SBP2 may pre-select ribosomes for Sec insertion (Copeland, Stepanik et al. 2001).
Selenoprotein synthesis requires a specific elongation factor, EFSec. This protein
does not bind with the SECIS element directly. It may bind to SECIS through interaction
with SBP2, which it does bind to (Fagegaltier, Hubert et al. 2000). Based on recent
studies, EFSec helps with UGA translation efficiency.

It interacts with only

SectRNA[Ser]Sec, and no other tRNAs. EFSec recruits the Sec specific tRNA. EFSec
along with SBP2, and the SECIS element form a SectRNA[Ser]Sec complex for recruiting
and delivering the SectRNA[Ser]Sec (Tujebajeva, Copeland et al. 2000)
Recently two new factors have been discovered to be involved in selenoprotein
synthesis. Ribosomal protein L30 is one of these. Similar to SBP2, L30 binds SECIS
specifically, and may anchor SECIS complex onto the ribosome, this in turn stimulates
UGA read-through activity (Chavatte, Brown et al. 2005). Another factor is SECp43,
which forms a complex with SectRNA[Ser]Sec. When SECp43 is knocked down there is an
overall decrease in selenoprotein synthesis (Xu, Mix et al. 2005), but the exact function
has yet to be elucidated.
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Thioredoxin reductase
Thioredoxin reductase (TrxR) is an antioxidant selenoprotein involved in
maintaining the redox state of the cell. TrxR had been discovered for many years before
it was known that is contained selenocysteine (Tamura and Stadtman 1996). Thioldisulfide reactions are important in controlling some proteins’ function and in protein
tertiary structure. Oxidation of SH groups could lead to improper folding or alter the
biological activity. The thioredoxin system is one of the major ways that the cell exerts
thiol redox control.
TrxR is a FAD containing homodimer, that is approximately 59 Kda in weight
(Luthman and Holmgren 1982). It is a member of the pyridine nucleotide-disulfide
oxidoreducatse family of enzymes. In mammals there are three isoforms; TrxR1 (the
dominant form) is the cytosolic protein, TrxR2 is found in the mitochondria and may help
protect the mitochondria from hydrogen peroxide (Lee, Kim et al. 1999), and TrxR3 is
found only in the testis and will also has glutathione reductase activity (Sun, Kirnarsky et
al. 2001). All three of these isoforms are selenoproteins (Sun, Wu et al. 1999), with the
UGA encoding Sec located at the penultimate C-terminal residue (Gladyshev, Jeang et al.
1996). Though there are three isoforms of TrxR in mammals, the focus of this thesis will
be on the predominant cytosolic enzyme, TrxR1.
TrxR acts as redox sensor (Sun, Wu et al. 1999). Reactive oxygen species (ROS)
have been shown to target the selenocysteine residue and oxidize the enzyme. However,
TrxR expression is increased with oxidative stress. This could be a possible explanation
for why the Sec residue is at the C-terminus (Sun, Wu et al. 1999). In addition, the Cterminus location of Sec allows for wider substrate recognition and easier access for
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inhibitors. Though thioredoxin (Trx) is the primary substrate of TrxR, it is also able to
reduce lipoic acid, protein disulfide-isomerase, selenodiglutathione, lipid hydroperoxides,
and dithiobis-nitrobenzoic acid (DTNB) (Holmgren 1977; Lundstrom and Holmgren
1990; Bjornstedt, Kumar et al. 1992; Bjornstedt, Hamberg et al. 1995; Arner, Nordberg et
al. 1996). TrxR also catalyzes the reduction of selenite to selenide, which has led to
speculation that TrxR is involved in selenoprotein synthesis (Bjornstedt, Odlander et al.
1996).
Regulation of TrxR1 expression
The promoter of TrxR contains an antioxidant response element (ARE) (Rundlof,
Carlsten et al. 2001). This is the target DNA sequence recognized by the Nrf2/Keap1
system. Nrf2 is a transcription factor that is usually bound by Keap1. When the cell
undergoes oxidative stress Nrf2 is released from Keap1 (Itoh, Wakabayashi et al. 1999).
This is triggered by a series of cysteine residues on Keap1 that sense changes in the redox
environment (Lee and Johnson 2004).

It has been previously demonstrated that

sulforaphane induces this response through TrxR (Hintze, Wald et al. 2003).
The thioredoxin system
The mammalian thioredoxin system consists of TrxR, thioredoxin (Trx), and
NADPH (Rundlof, Carlsten et al. 2001). Trx is a small 12 kDa redox active protein that
is reduced by TrxR using NADPH (Figure 2). Reduced thioredoxin is one of the major
players for maintaining proteins in their reduced state. Two of the proteins that Trx serves
as an electron donor are methionine sulfoxide reductases and peroxiredoxins (Chae, Kang
et al. 1999; Kim and Gladyshev 2005), both of which act as antioxidants in the cell.
Reduced Trx is also involved in an array of cellular processes including; synthesis of
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deoxyribonucleotides (Laurent, Moore et al. 1964), regulation of transcriptions factors
such as Fos and Jun, nuclear factor-κB, AP-1, and p53 (Abate, Patel et al. 1990; Schenk,
Klein et al. 1994; Ueno, Masutani et al. 1999), as an inhibitor of apoptosis signalregulating kinase (ASK1) (Saitoh, Nishitoh et al. 1998). Extracellularly Trx has roles in
immunoregulation as both a co-cytokine (Wakasugi, Tagaya et al. 1990) and as a
chemokine, but does not act through a chemkine receptor (Bertini, Howard et al. 1999).
Like TrxR1 and TrxR2, knockout studies with Trx resulted in embryonic lethality
(Matsui, Oshima et al. 1996).
Given the thioredoxin system’s involvement in a multitude of areas including cell
proliferation and antioxidant defense, it is not surprising that TrxR is highly expressed in
many types of cancers including breast, thyroid, prostate, liver, malignant melanoma, and
colorectal (Berggren, Gallegos et al. 1996; Gladyshev, Factor et al. 1998). Though the
thioredoxin system is upregulated in many tumors, this stimulation it is not a requirement
for all cancers.

Nonetheless, it does fit the requirements outlined in Hanahan and

Weinberg’s hallmarks of cancer. This consists of six altered traits that need to occur for
cancer to develop.

This includes self-sufficiency in growth signals, insensitivity to

antigrowth signals, evasion of apoptosis, sustained angiogenesis, and tissue invasion
(Hanahan and Weinberg 2000). Of these, only tissue invasion cannot be directly applied
to the thioredoxin system. Cell culture studies have been undertaken to examine the
effect of knocking down TrxR. In one study when TrxR1 was knocked down in mouse
lung carcinoma cells (LLC1) the tumor phenotype reverted back to that of a normal cell
as demonstrated through soft agar assays, morphology, and ability to produce tumors in
mice (Yoo, Xu et al. 2006).

Another study used a similar construct in human
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hepatocellular carcinoma cells knocking out TrxR, which inhibited growth of SMMC7721 cells (Gan, Yang et al. 2005). Given these cell culture studies and that TrxR is
overexpressed in many tumors it makes it a possible target for cancer therapy.
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Figure 2. Overview of oxidoreductase activities of the thioredoxin system
Presented is a schematic of the thioredoxin system as drawn from (Arner and Holmgren
2000). This is a depiction of the reduction of the oxidized Trx to the reduced form by
TrxR with NADPH. The reduced Trx is then used to reduce other proteins and serves as
an electron donor.
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Auranofin
Given that TrxR could be a target for cancer therapy, a specific inhibitor would be
ideal. One of these is the gold containing compound auranofin. Auranofin has been used
for the treatment of rheumatoid arthritis (Snyder, Mirabelli et al. 1987). The proposed
mechanism of this compound in the treatment of rheumatoid arthritis is through the
inhibition of NF-κB. This results in a decrease gene expression of proinflammatory
cytokines (Yamada, Sano et al. 1999; Jeon, Jeong et al. 2000). It is also an inhibitor or
TrxR with a Ki of 4 nM in the presence of 50 µM thioredoxin. At higher concentrations
it can also inhibit glutathione reductase and glutathione peroxidase (Gromer, Arscott et
al. 1998), however, these higher concentrations are not physiologically relevant.
Though it is FDA approved for treatment of rheumatoid arthritis, there have been
studies to promote its efficiency as cancer therapy. In one such study cisplatin-resistant
ovarian cancer cells were treated with up to 6 µM auranofin. This raised levels of
hydrogen peroxides in the cells and more importantly induced apoptosis. Interestingly
these cisplatin resistant cells had higher TrxR activities than the cisplatin sensitive cells,
which were less effected by treatment with auranofin (Marzano, Gandin et al. 2007). The
upregulation of TrxR, could be key in development of auranofin as a chemotherapeutic.
Arsenic
Arsenic exists in many forms, inorganic and organic, trivalent and pentavalent.
Arsenic exposure is primarily through the water supply, in particular artesian well water
(Tseng 1977). Contamination of arsenic in the water supply is a significant human health
issue in parts of Taiwan (Tseng 1977), Chile (Borgono, Vicent et al. 1977), Argentina
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(Hopenhayn-Rich, Biggs et al. 1998), Bangladesh (Nickson, McArthur et al. 1998), and
regions of China (Xia and Liu 2004).
Inorganic arsenite (trivalent) or arsenate (pentavalent) are the most likely forms to
be taken up by the body, since these are the most prevalent in the water supply. After
entering the body arsenate is reduced to arsenite (Tapio and Grosche 2006). Next, the
inorganic arsenite or arsenate undergoes a methylation pathway, in the liver, and is
excreted in the urine (Figure 3). Methylated forms of arsenic are excreted more easily
than inorganic.
Traditionally the methylation pathway has been thought of the as detoxification of
arsenic. Recently, this has been questioned for several reasons. Monomethylated forms
have been found to be the most cytotoxic, with pentavalent species not as cytotoxic as
trivalent species. Trivalent monomethylated species may help to contribute the effects of
arsenite exposure (Styblo, Del Razo et al. 2000). Monomehtlyarsonous acid (MMAIII)
has been found to be more cytotoxic than arsenite in liver cells (Petrick, Ayala-Fierro et
al. 2000).

Interestingly humans excrete much more MMAIII than other species of

mammals (Vahter 2002). Rodents primarily excrete dimethylarsinous acid (DMA).
It should be noted that rodents are less prone to arsenic induced cancer
development, perhaps due to the lower levels of MMAIII excreted.

12

Figure 3. Metabolism and methylation of arsenic
Pictured above is the methylation pathway for arsenic. Arsenic enters the bloodstream
as the pentavalent arsenate or as the trivalent arsenite through environmental exposure. It
then undergoes a series of reduction and methylation reactions and is excreted in the
urine. Drawn from (Cohen, Arnold et al. 2006).
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Chronic arsenic exposure is associated with: skin cancer, hyperpigmentation
(presence of dark pigmentation), hyperkeratosis (benign wart-like growths on the skin)
and Blackfoot disease (Tseng 1977). In addition to skin cancer, exposure to arsenic has
been implicated in cancer of the lung, kidney, liver, and bladder (Hopenhayn-Rich, Biggs
et al. 1998). According to a recently published 50 year study conducted in Chile, there is
an approximate 10 year latency period between exposure and mortality from arsenic
induced cancer from high levels of exposure in the water supply (Marshall, Ferreccio et
al. 2007).

Arsenic exposure has also been associated with diabetes mellitus,

hypertension, and cardiovascular and cerebrovascular diseases (Chen, Hsueh et al. 1995;
Chiou, Huang et al. 1997; Tseng, Tseng et al. 2002; Tseng, Chong et al. 2003).
Arsenicosis is most often the result of exposure from arsenic contaminated drinking
water. Arsenicosis includes symptoms of skin lesions that include hyperpigmentation,
hypopigmentation, keratosis, hyper keratosis, skin ulceration, and skin cancers (Yu, Sun
et al. 2007).
Even though arsenic exposure is associated with an array of diseases and cancers,
it has yet to be proven to cause cancer directly. Arsenite does not directly cause
mutagenesis, but in conjunction with other compounds can produce mutations. In one
study the use of the alkylating agent n-methyl-n-nitrosourea co-induced mutations in
Chinese hamster ovary cells when treated simultaneously with arsenite (Li and Rossman
1989). Another study with the same cell line observed an increase in mutations when
treated with ultraviolet light (Yang, Chen et al. 1992).

Arsenite results in a pro-

angiogenesis effect as determined by the chick chorioallantoic membrane model (Mousa,
O'Connor et al. 2007). Angiogenesis is important aspect of tumor formation as these are
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the blood vessels that feed them. In another study, MMAIII has been shown after 52
weeks of low exposure to induce hyperproliferation, anchorage independent growth, and
tumorigenicity in an immortalized human urothelial cell line (Bredfeldt, Jagadish et al.
2006). This study of MMAIII is the most recent to suggest that MMAIII be classified as a
carcinogen.
One popular hypothesis states that oxidative stress and free radicals, produced
during arsenic exposure, are linked to cancer (Kligerman and Tennant 2007). Reactive
oxygen species (ROS) include; hydrogen peroxide, superoxide anion, singlet oxygen, and
hydroxyl radical. Each of these species can cause damage to DNA and protein, but the
hydroxyl radical is the most often associated with DNA damage.

Usually a free

transition metal such as iron is needed for the hydroxyl radical to cause DNA damage in
the presence of peroxide (Kitchin and Ahmad 2003). ROS can cause DNA damage by
causing single strand breaks, deletions, and hydroxylation of 2’-deoxyguanosine. In
addition, oxidation at the C8 position of guanine may cause mispairing with adenine
during DNA replication resulting in a mutation (Kitchin 2001).
From a recent epidemiological study in Taiwan, arsenic exposure resulted in
increased reactive oxidants and decreased antioxidant capacity in vivo (Wu, Chiou et al.
2001). Arsenite and MMAIII have been shown to cause lipid peroxidation, protein
carbonylation, and oxidative DNA damage in urothelial carcinoma cell lines (Wang, Jan
et al. 2007). Similarly, in an in vivo study, higher levels of serum lipid peroxides were
found in populations exposed to arsenic through well water. This also correlated with
lower levels of nonprotein sulfhydryls (Pi, Yamauchi et al. 2002). Treatment with
arsenite induced free radical formation, most likely hydroxyl radicals produced by
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superoxide, as determined by fluorescence and ESR (Liu, Athar et al. 2001). In another
study arsenite at high concentrations produced superoxide and hydroxyl radicals and
induced DNA damage to cells in culture (Shi, Hudson et al. 2004). While arsenite
produces ROS more quickly, MMAIII can also induce formation of ROS (Eblin, Bowen et
al. 2006).

Also, of all the arsenic species MMAIII results in higher levels of ROS

(Schwerdtle, Walter et al. 2003).
In addition to oxidative stress, arsenic can cause a variety of changes that are
associated with development of cancer. Arsenite causes chromosome aberrations and
sister chromatid exchange (Barrett, Lamb et al. 1989). Arsenic, in particular arsenite,
suppresses DNA repair capacity. One mechanism could be the decreased expression of
the nucleotide excision repair gene ERCC1 both in vitro and in vivo (Andrew, Burgess et
al. 2006). Arsenic has also been associated with changes in methylation patterns. One
study found exposure to low levels of arsenite (nanomolar range) for 2-4 weeks caused
hypo and hypermethlyation of DNA in transformed kidney and lung cells (Zhong and
Mass 2001). Another study found hypermethlyation of cytosines in the p53 promoter
with A549 cells treated with low levels of arsenite for an extended period of time (Mass
and Wang 1997). A study of a constant low dose long exposure of arsenite in rat liver
cells resulted in gene expression changes in cell cycle regulation, signal transduction
pathways, stress response, apoptosis, cytokine production, and growth factor production
(Chen, Liu et al. 2001).
Arsenic trioxide
Arsenic trioxide (ATO) is a trivalent species of arsenic. Even though in high
doses it is toxic and is associated with carcinogenesis, it is also a FDA approved
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treatment of acute promyelocytic leukemia (APL) that is known as Trisenox. It has been
approved for the use of APL since 1998 (Bradley 2000). Trials are underway in testing
the effectiveness of ATO against solid tumors such as; gastric, ovarian and cervical,
bladder, neuroblastoma, glioblastoma (a type of brain tumor), breast, and lung
(bronchogenic carcinoma) (Dilda and Hogg 2007).
ATO is thought to work by several mechanisms. At low concentrations (0.1-0.5
µM), ATO induces differentiation of malignant promyelocytes through inactivation of the
promyelocytic leukemia-retinoic acid receptor α (PML-RARα) (Zhang, Westervelt et al.
2000). This protein is involved in the malignancy of APL by blocking differentiation. At
higher concentrations (0.5-2.0 µM), ATO induces apoptosis, which could be a result of
several mechanisms. The fist is that ATO causes a vast amount of ROS from which the
cell cannot recover (Jing, Dai et al. 1999). Another study has also shown that ATO
induces apoptosis through triggering the release of cytochrome c and activation of
caspase-3 in APL cells (Cai, Shen et al. 2000). However, a recent study has shown that it
also inhibits the selenoprotein TrxR, and this could be part of the mechanism (Lu, Chew
et al. 2007).
Arsenic and selenium interactions
Arsenic and selenium are known to interact in what is known as the mutual
sparing effect, first described by Moxon during studies of seleniforous grains (Moxon
1938). This implies that when selenium levels are low, arsenic levels are higher, and
when arsenic levels are low, selenium levels are higher. This mutual sparing effect has
also been demonstrated in animal and cell culture studies in which levels of selenium and
arsenic were varied (Levander 1977; Styblo and Thomas 2001).
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Another key finding in the interaction of selenium and arsenic was the discovery
of the seleno-bis(S-glutathionyl) arsinium ion (Gailer, George et al. 2002; Gailer, George
et al. 2002). This was excreted in the bile of rabbits treated with selenium and arsenic.
Recently we published a study on the affect of trivalent arsenicals on selenoprotein
synthesis in a keratinocyte model.

It was found that arsenite decreased selenium

incorporation into selenoproteins. However, MMAIII induced selenium incorporation into
TrxR, while decreasing selenium incorporation into smaller selenoproteins, such as
cGPx.
In the studies reported in this thesis, our goal was to answer two key questions; 1)
Is TrxR1 required for selenoprotein synthesis? and 2) What is the molecular mechanism
of the induction of TrxR1 by exposure to MMAIII?
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CHAPTER TWO: MATERIALS AND METHODS
Materials
Sodium selenite and sodium arsenite were obtained from Acros Organics (Geel,
Belgium).

75

Se radioisotope (in the form of selenite), was purchased from University of

Missouri Research Reactor (MURR, Columbia, MO).
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S-methionine/cysteine label was

obtained from Amersham BioSciences (Piscataway, NJ). Auranofin was from Axxora
LLC (San Diego, CA).

ATO was obtained from Acros Organics (Geel, Belgium).

MMAIII was from Dr. William Cullen, Department of Chemistry, University of British
Columbia (Vancouver, Canada). All other reagents used were of the highest grade
obtainable.
Cell culture
A549 cells were obtained from the American Type Culture Collection
(Manassas, VA). Cells were cultured in Dulbecco’s modification of Eagle’s medium
(DMEM) with L-glutamine, sodium pyruvate, and 4.5 g/L glucose.

This was

supplemented with 100 µg/mL streptomycin, 100 IU/mL penicillin (Mediatech, Herndon,
VA), and 10% fetal bovine serum (FBS) (Equi-tech Bio, Kerrville, TX).

WI-38 cells

were from the American Type Culture Collection and were cultivated in Eagle’s
Minimum Essential Medium (EMEM) supplemented with Earle’s balanced salt solution,
non-essential amino acids, and sodium pyruvate. Supplementation of the EMEM medium
included 10% FBS and 50 µg/mL streptomycin, and 50 IU/mL penicillin. All cells were
maintained at 37°C, with 5% CO2, with a humidified atmosphere as a monolayer.
Population doublings of WI-38 cells were recorded at each passage by cell counting
using a hemacytometer, and no cells were used in experiments that exceeded a population
doubling of 34.0.
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Cell viability assay
To determine the cytotoxicity of arsenite, MMAIII, ATO, and auranofin, MTT
assays were performed.

Cells were cultured in 96 well plates, at approximate

concentrations of 2,500-10,000 cells per well (depending on the compound being tested)
in 100 µL of appropriate media for the cell type. Cells were grown to approximately
70% confluence before treatment, with the exception of ATO treated cells which were
grown to 40% confluence. Arsenite was tested at concentrations of 1, 3, 9, 18, 36, 72,
144 µM. MMAIII was tested in the following concentrations in A549: 1, 3, 6, 9, 13, 17,
21 µM, and 0.2, 0.5, 1, 3, 6, 9, 12, 15, 18, 21, 24, 28 µM in WI-38. Auranofin was
assessed at 0.1, 0.25, 0.5, 0.75, 0.9, 1, 3, 7, 10, 20, 30, 50 µM. ATO was tested at 0.25,
0.5, 0.7, 0.9, 1, 3, 7, 10, 20, 40, 50, 70 µM in A549 cells. Cells were incubated for 24
hours with either arsenite, MMAIII, auranofin before adding 1.2 mM of a tetrazolium dye,
3- (4,5 dimethylthiazol-2-yl)- 2,5-diphenyl tetrazolium bromide (MTT) (Amresco, Solon,
OH). For cytotoxicity of ATO the cells were incubated for 48 hours before addition of
MTT. Plates were then incubated for 4 hours at 37°C in a humidified atmosphere of 5%
CO2. To solubilize the dye, 100 µL of a stop solution (10% SDS and 5 mM HCl) was
added and the plates were incubated an additional 14-20 hours before analysis. The
reduced formation of product was measured at an absorbance of 570 nm using a
Molecular Devices, SpectraMax 190 spectrophotometer (Sunnyvale, CA). Cell viability
was calculated as a percentage compared to control with error being the standard
deviation from triplicate wells.
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Radioisotope labeling
A549 or WI-38 cells were cultured in 6-well plates and grown to 70% confluence.
Approximately 2 µCi of 75Se, in the form of selenite (University of Missouri), and 10 nM
of unlabeled sodium selenite were added to each well. Just prior to labeling, various
concentrations of arsenite (0, 2, 6, or 10 µM in A549 cells), MMAIII (0, 2, or 6 µM in
A549, and 0, 0.2, or 2 µM in WI-38 cells), or ATO (0, 1, 2.5, 5, or 10 µM in A549 cells)
were added. However, when adding auranofin (0.1, 0.25, 1 or 3 µM) cells were treated
for 4 hours, to allow inhibition of TrxR, prior to addition of isotope. The cells were
incubated at 37°C with 5% CO2 for 24 hours before harvesting when treated with
arsenite, MMAIII, or auranofin. Cells treated with ATO were harvested after 48 hours of
treatment. To monitor how arsenite, auranofin, and ATO effect overall protein synthesis
30 µCi of 35S, in a cysteine/methionine mixture, was added to each well, with A549 cells
cultured in a cysteine/methionine free DMEM.
Cells were harvested by washing the well with Dulbecco’s phosphate-buffered
saline (DPBS), then upon removal adding 1x trypsin-EDTA and incubating at 37°C for 4
minutes. Cells were collected by centrifugation and washed with DPBS. Cell pellets
were resuspended in 200 µL of lysis buffer (50 mM tricine (pH 8.0), 0.1 mM
benzamidine, 0.5 mM EDTA, and 1 mM DTT). Cells were lysed by sonication for 6-8
sec, at a power setting of 4 W, using a Model 100 sonic dismembrator (Thermo Fisher
Scientfic, Pittsburgh, PA). The lysates were then centrifuged at 13,000 rpm for 7 minutes
at 4°C. Lysates were analyzed for 75Se using a Wallac Wizard Gamma Counter, Model
1470 (PerkinElmer, Wellesly, MA).

35

S isotope levels in cell extracts were determined

by liquid scintillation using a Packard TriCarb 2900 TR counter (PerkinElmer, Waltham,
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MS). Protein concentration was quantified through Bradford assay according to the
method in (Bradford 1976) using bovine serum albumin as a standard. Approximately
15- 25 µg of protein (depending on the study) from crude cell extract was separated by
SDS-PAGE gel (5% stacking gel and 15% resolving gel), and exposed to a
phosphoimaging screen (Molecular Dynamics). Selenoproteins were visualized and in
some cases quantified, using Image Quant software (Molecular Dynamics, Sunnyvale,
CA).
Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of TrxR1
gene expression
Cells were cultured in 25 cm2 flasks and treated with 0, 2, or 10 µM arsenite, or
MMAIII for 24 hours.

Cells were harvested by washing with 1x DPBS, and then

incubated for 4 min with 1x trypsin-EDTA. The cells were then washed with 1x DPBS
treated with diethylpyrocarbonate (DEPC) (0.1%).

RNA was isolated with a

ChargeSwitch Total RNA Cell Kit (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions. Concentrations of RNA were determined by ultraviolet
(UV)-visible spectrophotometry at 260 nm using an Agilent 8453 UV-visible
spectrophotometer (Ageliant Technologies, Santa Clara, CA).

Complimentary DNA

(cDNA) was synthesized from 0.5 µg of RNA using an iScript cDNA synthesis kit
(BioRad, Hercules, CA) according to the manufacturer’s instructions.
Primers used included (listed forward then reverse) TrxR1: 5’AGCTCAGT
CCACCAATAGTGA-3’ and 5’-GGTATTT TTCCAGTCTTTTCAT-3’; β-actin: 5’CATGTACGTTGCTATCCA-3’ and 5’-CTCCTTAATGTCACGCACGAT-3’; Trx: 5’GCAGATCGAGAGCAAGACTG-3’

and
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5’-CTCCAGAAAATTCACCCACC-3’;

cGPx: 5’-GGACTACACCCAGATGAA-3’ and 5’-CAAGGTGTTCCTCCCTCGTAG3’. All RT-PCR was done with a Bio-Rad I-Cycler (BioRad, Hercules, CA). Each
reaction was a total volume of 25 µL consisting of SYBRgreen supermix (Bio-Rad,
Hercules, CA) four oligonucleotides at a concentration of 0.2 mM, forward and reverse
primers (at a concentration of 0.2 µM each), and 5 µL of 1:100 diluted cDNA. Reaction
conditions were as follows; the first cycle at 95.0°C for 3 minutes, followed by 40 cycles
95.0°C for 10 sec and 55.0°C for 45 sec. With the cGPx-specific primers the following
reaction conditions were used; a single cycle at 94.0°C for 3 minutes, subsequent 40
cyles of 94.0°C for 30 sec, 55°C for 30 sec, and 70.0°C for 30 sec. Melt curves were
used to determine formation of single product. Efficiency of amplification of each primer
pair was calculated with a 10-fold dilution series with untreated cDNA. The Pfaffl
method (Pfaffl 2001) was used to determine the relative expression (fold) for each of the
genes of interest using β-actin as an internal standard.
TrxR activity assays
A549 or WI-38 cells were cultured in 75 cm2 flasks in appropriate cell culture
media. Cells were treated with varying concentrations of arsenite (0, 2, or 6 µM),
auranofin (0, 0.25, 1, or 3 µM), or MMAIII (0, 2 or 6 µM in A549 cells and 0, 0.2, or 2
µM in WI-38 cells) for 24-48 hours (depending upon the compound being tested) before
harvesting as described above. Cells pellets were resuspended in a lysis buffer of 5 mM
potassium phosphate pH 7.4 and 0.5 mM EDTA and sonicated as described above.
Crude cell extracts were centrifuged at 11 krpm for 7 min at 4 °C. NADPH dependent
reduction of dithiobis-nitrobenzoic acid (DTNB) was determined according to Levander,
with minor modifications (Smith and Levander 2002).
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Protein concentration was

determined by Bradford assay as described above and according to (Bradford 1976).
Cells extracts were diluted in a buffer consisting of 10 mM potassium phosphate pH 7.4,
154 mM potassium chloride, and 1 mg/mL of bovine serum albumin (BSA) to a final
concentration of 1 mg/mL.

The reaction buffer consisted of 500 mM potassium

phosphate pH 7.8, 50 mM potassium chloride, 10 mM EDTA, and 0.2 mg/mL BSA. To
each well containing reaction buffer in a 96-well plate, 24 mM NADPH (dissolved in
0.01% sodium bicarbonate) was added before 20 µM DTNB. To measure the gold
inhibitable activity to differentiate TrxR from glutathione reductase (GR), cell extracts
were pre-incubated with 1 µM auranofin for 20 minutes at room temperature to allow for
complete inhibition of TrxR. 50 µg of protein was used to begin the reactions in a 96
well plate, and each individual sample was run in duplicate. Reduction of DTNB was
followed using a SpectraMax 190 spectrophotometer (Molecular Devices, Sunnyvale,
CA) at 412 nm, at a temperature of 37°C, taking readings every 15 sec for 3 minutes.
Slopes were determined for each sample, and the rates of samples incubated with
auranofin were subtracted to determine total TrxR activity. Activity of TrxR is given as
nmol/min/mg of protein, with standard deviation as the error.
Transient siRNA knockdowns
A549 cells were seeded in 6 well plates and grown to 60% confluence. siRNA
targeting the mRNA encoding mitogen activated protein kinase1 (MK), Trx, and TrxR1
were obtained through Qiagen (Valencia, CA). A non-silencing fluorescent control was
used to determine siRNA transfection efficiency. Transfection complexes were prepared
by a mixture of serum free media, HiPerfect Transfection Reagent (Qiagen, Valencia,
CA), and 5 nM target siRNA, and incubated for 10 minutes at room temperature to allow
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transfection complexes to form.

This was added dropwise to cells.

Immediately

following addition of 5 nM siRNA, cells were treated with 3 µM auranofin to inhibit
existing TrxR. Cells were incubated for 24 hours with siRNA and auranofin before
removing media and labeling with 2 µCi of

75

Se (selenite) and incubating an additional

24 hours. Cells were harvested as described above in previous labeling experiments. Trx
and TrxR1 knockdowns were assessed at the mRNA level by real-time reverse
transcriptase-PCR as described above.
Promoter fusion luciferase constructs assay
Luciferase promoter fusion constructs of human wild-type TrxR1, mutant TrxR1,
and rat quinone reductase (QR) were a generous gift from Dr. Korry Hintze (Department
of Nutrition and Food Sciences, Utah State University).

Cells were seeded in 24-well

tissue culture plates. A549 cells were seeded at a concentration of 100,000 per well, and
WI-38 cells at 60,000 per well in 500 µL of the appropriate medium. Transfection
complexes were prepared with 1 µg of plasmid DNA (pDNA) of all three constructs in
A549, 1 µg of pDNA of TrxR1 and mutated TrxR1 constructs in WI-38, and 2 µg of QR
in WI-38 cells. In addition to the pDNA the following was added to complete the
transfection complexes; Superfect reagent (Qiagen, Valencia, CA) was added in a 7.5
µL/1 µg pDNA ratio, 540 µL Optipro serum free medium (Gibco, Carlsbad, CA), and 2.5
ng of a control plasmid expressing Renilla luciferase (PRL-SV40) (Promega, Madison,
WI) for all transfections, with the exception of 12.5 ng of PRL-SV40 for QR
transfections in WI-38 cells. Cells were incubated with transfection complexes and 300
µL of the appropriate medium with serum for 3 hours. The medium was then changed
and MMAIII added in the following concentrations in triplicate; 0, 2, or 6 µM in A549
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cells and 0, 0.2, or 2 µM in WI-38 cells, and incubated for 24 hours before assaying.
Luciferase assay was completed with the Dual Luciferase Reporter Assay System
(Promega, Madison, WI) according to the manufacturer’s instructions with the exception
of using 2x passive lysis buffer, followed by scraping for the WI-38 cells. A Glomax
luminometer (Promega, Madison, WI) was used to measure luminescence. Data was
plotted as a fold ratio of luciferase to renilla activity, with standard deviation as error.
Statistical Analysis
All statistical analyses were performed with Microsoft Excel for Mac 2004
(Microsoft, Redmond, WA). Unpaired t-tests or one way ANOVA were performed when
appropriate. All significance was evaluated at p<0.05.
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CHAPTER THREE: RESULTS AND DISCUSSION - INHIBITORS OF
THIOREDOXIN REDUCTASE AND THEIR EFFECTS ON SELENIUM
METABOLISM

Overview
TrxR is a selenoprotein involved in controlling the redox state of the cell. Its
primary substrate, thioredoxin (Trx), is required for many cellular activities including:
cell proliferation, DNA synthesis, and regeneration of peroxyredoxins and methionine
sulfoxide reductase (Laurent, Moore et al. 1964; Chae, Kang et al. 1999). In in vitro
TrxR can also reduce selenite to selenide (Bjornstedt, Odlander et al. 1996). This has led
to speculation that TrxR is somehow involved in selenoprotein synthesis, since selenide
is the form of selenium utilized by selenophosphate synthetase2 (SPS2).
In this study, three inhibitors of TrxR were used to observe their effects on
selenium metabolism. The first compound tested was arsenite (Figure 4 A), a trivalent
inorganic form of arsenic mainly found in arsenic contaminated water supplies. Arsenic
exposure is associated with cancer of the liver, lung, kidney, and bladder (Kitchin 2001).
ATO is also a trivalent form of arsenic that is used to treat acute promyelocytic leukemia
(Figure 4 B). It was recently found to be an inhibitor of TrxR (Lu, Chew et al. 2007).
Auranofin is a well-known inhibitor of TrxR (Gromer, Arscott et al. 1998) (Figure 4 C).
It is also a current therapy for rheumatoid arthritis.
We tested the hypothesis that TrxR is involved in selenium metabolism. This was
accomplished by looking at the effects of three known inhibitors of TrxR on selenium
metabolism and siRNA knockdowns targeting TrxR1 and Trx.
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Figure 4. Structures of arsenite, ATO, and auranofin
Pictured above are the structures of arsenite (A), ATO (B), and auranofin (C) as obtained
from PubChem compound (arsenite: CID 544, ATO: CID 261004, auranofin: CID
6333901) .
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Evaluation of cytotoxicity of arsenite in A549 cells
MTT assays were used to determine toxicity of arsenite in A549 cells. Cells were
treated for 24 hours with varying concentrations of arsenite.

Results from these

experiments show that at approximately 100 µM of arsenite, there is a 50% reduction in
cell viability (Figure 5). This is a non-physiologically relevant concentration since it is
thought that environmental exposure to arsenic is mimicked in cell culture by levels in
the low micro molar or nanomolar levels (Hughes 2002). A549 cells are somewhat
resistant to arsenite as compared to human keratinocytes used in another related study
(Ganyc, Talbot et al. 2007). HaCat cell viability was reduced to 50% by approximately
22 µM arsenite. Since the overarching goal is to determine the impact of arsenite on
selenoprotein synthesis, from the results of this assay it was determined that future
concentrations used to treat A549 cells would be in the 1-10 µM range, and that these
concentrations would not significantly affect cell viability during short term (24-48
hours) experiments.
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Figure 5. A549 cells are resistant to exposure to low micromolar levels of arsenite
Cytotoxicity of arsenite was determined in A549 cells after 24 hours of exposure using
MTT assays. The absorbance of the treated cells was compared to untreated cells to
determine the relative percent cell viability. Data points are the mean of triplicate wells,
with the error plotted as standard deviation. The data plotted are from a representative
experiment taken from three separate independent experiments.
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Arsenite treatment of cells reduces selenium incorporation into selenoproteins
In order to determine whether exposure to arsenite affects selenium metabolism,
we followed selenium incorporation into selenoproteins by radioisotope labeling with
75

Se. The results indicate that exposure to A549 cells to 6 µM of arsenite, a decrease in

general selenoprotein synthesis occurs, particularly TrxR (Figure 6). At 10 µM there is a
near abolishment of selenium incorporation into selenoproteins. It must be noted that the
cells are still viable at this point, with only minor rounding. Arsenite does not inhibit
general protein synthesis as determined by
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S-methionine/cysteine labeling in add in

new data as it is generated.
TrxR is the predominant selenoprotein expressed in A549 cells, and it is well
established that this cell line expresses very little cGPx (Avissar, Finkelstein et al. 1996).
In a previous study, using a keratinocyte cell line, cGPx served as one of the markers for
selenoprotein synthesis (Ganyc, Talbot et al. 2007). This cannot be accomplished with
A549 cells. However, selenium incorporation into smaller (unidentified) selenoproteins
decreases along with TrxR in the presence of arsenite.
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Figure 6. Exposure of A549 cells to arsenite inhibits incorporation of selenium into
selenoproteins
A549 cells were exposed to arsenite (0, 2, 6, or 10 µM) immediately followed by
radiolabeling with 75Se (selenite) for 24 hours. Cells were subsequently harvested and 30
µg of protein were separated by SDS-PAGE (15%). Selenoproteins were visualized by
phosphorimage analysis. TrxR was identified as the predominant labeled selenoprotein
by its size (59 KDa) using a standard protein marker (not shown).
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Arsenite does not significantly effect the level of mRNA encoding TrxR1
To determine whether arsenite affects production of TrxR1 mRNA, real time RTPCR was used. Arsenite had no significant effect on the mRNA levels that encode TrxR1
(p>0.05) (Figure 7). Even in cells treated with 10 µM arsenite, there is no significant
change in the levels of transcript. This differs from the labeling results in which arsenite
decreased TrxR synthesis in a concentration dependent manner beginning at treatment
with 6 µM. TrxR1 was chosen as the selenoprotein marker given its abundance in A549
cells (Avissar, Finkelstein et al. 1996). This demonstrates that arsenite is not effecting
TrxR1 at the level of transcription, and must be effecting incorporation of selenium into
selenoproteins.

It should be noted that this is in contrast to data that was previously

obtained in a skin cell model in which TrxR1 expression levels increased with the
addition of arsenite (Ganyc, Talbot et al. 2007). At the biochemical level arsenite is
known to be a potent inhibitor of TrxR1 (Holmgren 1977). Based on these results two
possible mechanisms can explain the decreased incorporation of selenium. The first, that
direct inhibition of TrxR by arsenite reduces the level of selenide in the cell, assuming
TrxR is needed for this step (Bjornstedt, Odlander et al. 1996). The second that a
glutathione conjugate, GSSeAs-, is formed, blocking selenium metabolism.
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Figure 7. Treatment of A549 cells with arsenite does not significantly alter the levels
of mRNA encoding TrxR1
Cells were treated for 24 hours with 0, 2, or 10 µM arsenite followed by isolation of RNA
for real time RT-PCR analysis. β-actin was used as an internal standard. Relative
expression (fold) plotted is an average of multiple experiments with cultures grown in
triplicate in each experiment. Error bars represent standard deviation. No statistical
significance was found between TrxR1 transcript levels in cells treated with arsenite as
determined by one-way ANOVA (p> 0.05).
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Arsenite inhibits TrxR activity
Previous studies have shown that arsenite inhibits TrxR in vitro (Holmgren 1977).
To determine whether that arsenite treatment of A549 cells results in altered TrxR
activity, cells were cultured with arsenite for 48 hours at 0, 2, and 6 µM. At 2 µM
arsenite TrxR activity is reduced by about 50% (Table 1). There was complete inhibition
of TrxR in cells treated with 6 µM arsenite. Since arsenite is not effecting TrxR at the
level of transcription, nor protein levels as determined by immunoblotting (data not
shown), it may be acting solely as an inhibitor of TrxR. Whether this inhibition is tied to
overall selenoprotein synthesis is still unknown. Nonetheless, this supports the notion
that TrxR is involved in selenoprotein synthesis. It is known that it can reduce selenite to
selenide in vitro and it has been speculated that it does have a role in selenoprotein
synthesis, but this has yet to be demonstrated (Bjornstedt, Odlander et al. 1996). It then
becomes important to examine other inhibitors of TrxR to see if they produce the same
decrease in selenoprotein synthesis.
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Table 1. Effect of exposure to arsenite on TrxR activity
TrxR activities were determined by DTNB assay as previously described (Smith and
Levander 2002). A549 cells were cultured in the presence of 0, 2, or 6 µM arsenite for
48 hours prior to harvesting. The average activity is derived from a multiple experiments
with duplicate cultures in each treatment group.

Concentration
of Arsenite
0 µM
2 µM
6 µM

Activity
(nmol/min/mg)
7.71
3.89
0.977
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Standard
Deviation
1.53
1.28
0.849

Cytotoxicity of arsenic trioxide
Since arsenite inhibited TrxR activity in A549 cells, another trivalent arsenical,
ATO, was examined. ATO is used for treatment of acute promyelocytic leukemia, and
differs from arsenite structurally (Figure 4). Often in cell culture studies examining the
effects of ATO, arsenite is used interchangeably, even though it is not the trivalent
arsenical that is used in cancer therapy. ATO was also recently identified as an inhibitor
of TrxR (Lu, Chew et al. 2007). It then becomes important to confirm that ATO causes
the same phenotypic changes as arsenite regarding selenoprotein synthesis.
As with arsenite, an MTT assay was used to determine the toxicity of ATO in
A549 cells. At 60 µM ATO there is a 50% reduction in cell viability (Figure 8). In a
recent study it was found that 0.25 µM inhibited TrxR in vitro, and cell growth decreased
with exposure to 2.5 µM ATO in human breast cancer (MCF-7) cells (Lu, Chew et al.
2007). Based on these results we carried out studies to follow selenium metabolism using
concentrations of 0, 1, 2.5, and 5 µM ATO in the radiolabeling experiments.
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Figure 8. Toxicity of ATO in A549 cells
Cytotoxicity of ATO was determined by MTT assay. A549 cells were treated with a
range of concentrations of ATO for 48 hours before addition of MTT. The absorbance of
reduced tetrazolium dye after solublization was compared to untreated cells to determine
the relative viability of cells. Data points are the mean of triplicate wells, with the error
plotted as standard deviation. This is a representative experiment taken from three
independent experiments.
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ATO blocks incorporation of selenium into selenoproteins
Even though they are used interchangeably in cell culture studies, it is important
to determine whether ATO exhibits the same phenotype as arsenite on selenium
metabolism when cultured with A549 cells. Similar to arsenite, ATO treatment of A549
cells leads to decreases in selenoprotein synthesis as demonstrated by 75Se radiolabeling
(Figure 9 A). This inhibition is observed in cells treated with a concentration of 2.5 µM
and continues in a concentration dependent manner. In addition, ATO does not effect
general protein synthesis as determined by
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S labeling studies (Figure 9 B).

In a

previous study, 2.5 and 5 µM ATO were found to inhibit TrxR1 in MCF-7 breast cancer
cells by 40% (Lu, Chew et al. 2007). It is interesting that two trivalent inorganic
arsenicals have the same effect on selenoprotein synthesis where one, arsenite, is
associated with cancer, and the other, ATO, is associated with the treatment of cancer.
The next step was to look at another known inhibitor of TrxR, one that did not contain
arsenic, to see if the phenotype of a decrease in selenoprotein synthesis occurs.
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Figure 9. ATO inhibits selenoprotein synthesis, but not general protein synthesis in
A549 cells
A549 cells were cultured in DMEM and treated with either 0, 1, 2.5, or 5 µM ATO and
labeled with 2 µCi of 75Se (A) or 35S (B) in triplicate for 48 hours. Cells were harvested
and 15 µg of protein from extracts were separated by SDS-PAGE (15%). Selenoproteins
(75Se) and general protein synthesis (35S) were visualized by phosphorimage analysis.
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Cytotoxicity of auranofin
Auranofin is a known inhibitor of TrxR (Gromer, Arscott et al. 1998). It is a gold
compound that is currently used in the treatment of rheumatoid arthritis. As with arsenite
and ATO, the cytotoxicity of auranofin in A549 cells was determined by MTT assay.
Cells were treated with auranofin for 24 hours at varying concentrations.

A 50%

reduction in cell viability is observed in cell treated with 15 µM auranofin (Figure 10).
A549 cells are much more sensitive to auranofin than ATO and arsenite. This assay was
used to determine which concentrations of auranofin should be used in radiolabeling
studies that would be sub-toxic to A549 cells. From the MTT assay and the literature on
auranofin inhibiting TrxR, it was decided that 0, 0.1, 0.25, 1 and 3 µM auranofin would
be used in studies to follow selenium metabolism.
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Figure 10. Auranofin is toxic to A549 cells
Cytotoxicity of auranofin was determined by MTT assay. A549 cells were treated with a
range of concentrations of auranofin, in triplicate for 24 hours before the MTT dye was
added. This is a representative experiment taken from three independent experiments.
Each point is an average of three wells, and error is standard deviation.
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Auranofin inhibits selenoprotein metabolism
Based on its ability to inhibit TrxR, we determined whether treatment of A549
cells with auranofin would affect incorporation of selenium into selenoproteins.
Auranofin indeed inhibited incorporation of selenium into selenoproteins in a
concentration dependent manner (Figure 11 A). At treatment with 1 µM there is a
significant decrease in selenoprotein synthesis. Nearly all incorporation of selenium into
selenoproteins is abolished, with the exception of TrxR, in cells treated at 1 or 3 µM
auranofin. There is a concentration dependent decrease in levels of TrxR seen beginning
at 1 µM.

Neither treatment with 0.1 or 0.25 µM auranofin had any effect on

selenoprotein synthesis. Auranofin does not inhibit general protein synthesis as shown
by

35

S labeling (Figure 11 B). This was tested at the same concentrations used to

examine the effect of auranofin on selenoprotein synthesis.
The data presented thus far supports the hypothesis that TrxR is critical to
selenoprotein synthesis. So far, three inhibitors of TrxR have decreased incorporation of
selenium into selenoproteins. Though it must be made certain that TrxR is inhibited in
A549 cells treated with auranofin before proceeding with other studies.
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Figure 11. Auranofin treatment of A549 cells results in inhibition of incorporation
of selenium into selenoproteins, but does not inhibit general protein synthesis
A549 cells were cultured in DMEM and treated with either 0, 0.1, 0.25, 1, or 3 µM
auranofin and radiolabeled with either

75

Se (A) or

35

S (B) 4 hours after addition of

auranofin. Protein from cell extracts were separated by SDS-PAGE (15%) and visualized
by phosphorimaging.

44

Auranofin treatment of A549 cells leads to lower TrxR activity
Cells were cultured with increasing concentrations of auranofin and subsequently
harvested after 24 hours. TrxR activity was determined by following the reduction of
DTNB (Smith and Levander 2002). At treatment with 1 µM auranofin a significant
decrease in TrxR activity is observed (Table 2). With treatment at 3 µM the activity is
decreased even further, to approximately one-fifth of that of control. These results were
expected since auranofin is a known potent inhibitor of TrxR both in vitro and in vivo
(Gromer, Arscott et al. 1998).
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Table 2. Treatment of A549 cells leads to inhibition of TrxR
A549 cells were treated with increasing concentrations (0, 0.25, 1, or 3 µM) of auranofin
for 24 hours. TrxR activities were determined by DTNB assay, as previously described.
The average TrxR activity is derived from multiple experiments with duplicate cultures.

Concentration
of Auranofin
0 µM
0.25 µM
1 µM
3 µM

Activity
(nmol/min/mg)
10.4
10.3
7.82
1.99

Standard
Deviation
1.86
1.83
1.19
0.807
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Neither Trx or TrxR are required for selenoprotein synthesis
To confirm that TrxR1 is involved in the metabolism of selenium, transient
siRNA knockdowns were used. It is not only important to look at the effect of a
knockdown of TrxR1, but also its primary physiological substrate Trx. The possibility
exists that the lack of reduced Trx could be responsible for the decrease in selenoprotein
synthesis observed when cells were treated with known TrxR inhibitors. It is also
important to inhibit the existing TrxR in the cells with chemical inhibitors to reduce
existing enzyme activity. This was accomplished by simultaneously treating A549 cells
with 3 µM auranofin, a concentration that inhibits TrxR activity (Table 2), and siRNA
targeting Trx, TrxR1, or a negative control for 24 hours. Cells were treated with siRNA
and auranofin for 24 hours then the media was removed and replaced with fresh media
without auranofin.

75

Se was added to monitor selenoprotein synthesis.

This pre-

treatment with auranofin was tried in various iterations, with similar to results to the ones
presented (Figure 12), before deciding which method was the best for inhibiting the
existing TrxR and successfully knocking down TrxR1 and Trx. It was also important to
have a transient knockdown of a protein unrelated to selenoprotein synthesis to ensure
that any effects seen with the knockdowns of TrxR1 or Trx would be specific. For this
we chose Map kinase1 (MK), which has no known linkage to selenium metabolism,
selenoprotein synthesis, Trx, or TrxR1.
Efficiency of transfection was determined by using a non-specific fluorescent
probe. Transfected cells were counted by direct optical fluorescence microscopy. The
transfection efficiency was found to be 65.7%.
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From the labeling with

75

Se, it was shown that a knockdown of TrxR1 did not

result in a decrease in overall selenoprotein synthesis (Figure 12). The same was true for
the knockdown of its substrate, Trx. The only band that shows a significant decrease in
any selenoprotein was that of TrxR, when the siRNA was introduced into the cells.
There is no change in the incorporation of selenium into selenoproteins in cells without
siRNA treatment demonstrating that the exposure to auranofin and its removal did not
reduce new selenium incorporation. Cells treated with MK siRNA also did not exhibit
any changes in selenoprotein synthesis. We then sought to confirm that both expression
of TrxR1 and Trx were decreased before further speculation can be made about the role
of TrxR1 in selenoprotein synthesis.
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Figure 12. siRNA knockdowns of Trx and TrxR1 reveal no role in selenoprotein
synthesis
A549 cells were treated with 5 nM siRNA targeting the mRNA molecules encoding map
kinase1 (MK), thioredoxin (Trx), or thioredoxin reductase 1 (TrxR1). Cells were pretreated with 3 µM auranofin to inhibit existing TrxR. After 24 hours the media was
removed, replaced with fresh media without auranofin and

75

Se was added. The cells

were then incubated an additional 24 hours to assess selenium incorporation. 20 µg of
protein from cell lysates were separated by SDS-PAGE (15%).
selenoproteins were visualized by phosphorimaging.
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Radiolabeled

Expression levels of TrxR1 and Trx in siRNA treated cells

To confirm that siRNA knockdowns were efficient, the mRNA levels of both
TrxR1 and Trx were analyzed. Cells treated with the Trx siRNA construct show a
significant decrease in Trx mRNA expression levels as determined by real time RT-PCR
(Figure 13 A).

TrxR1 mRNA levels are unaffected by the Trx siRNA construct.

Similarly, TrxR1 mRNA levels are severely decreased in cells treated with TrxR1 siRNA
(Figure 13 B). Trx mRNA levels are unchanged by treatment with TrxR1 mRNA. This
shows that both of the constructs are efficient and specific in reducing mRNA levels.
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A

B

Figure 13. Confirmation of siRNA knockdowns using real time RT-PCR analysis of
Trx and TrxR1 mRNA levels
Real-time RT-PCR was used to monitor efficiency of the Trx and TrxR1 knockdowns by
analyzing mRNA levels. β-actin was used an internal standard for analysis. Trx (A)
mRNA levels were indeed much lower in cells treated with Trx siRNA as compared to
control and TrxR1 knockdowns. Likewise, TrxR1 (B) mRNA levels were reduced by
treatment with TrxR1 siRNA. Mean relative expression (fold) in (A and B) is derived
from a representative experiment with duplicate cultures that were analyzed in triplicate.
Error bars represent standard deviation.
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CHAPTER FOUR: CONCLUSIONS - INHIBITORS OF THIOREDOXIN
REDUCTASE AND THEIR EFFECT ON SELENIUM METABOLISM

There has been much speculation on the role of TrxR in selenoprotein synthesis
(Kumar, Bjornstedt et al. 1992; Ganther 1999; Papp, Lu et al. 2007). It is known that
TrxR can reduce selenite to selenide (Bjornstedt, Odlander et al. 1996). Selenide is the
primary form of selenium utilized by selenophosphate synthetase 2 (SPS2) to produce
selenophosphate (Tamura, Yamamoto et al. 2004). Though this reaction with TrxR
occurs in vitro, there is lacking in vivo data.
In this study we have demonstrated that TrxR is not likely involved in
selenoprotein synthesis. Even though three known inhibitors of TrxR decreased selenium
incorporation into selenoproteins, knockdown of TrxR1 expression resulted in no change
in incorporation of selenium into selenoproteins. The existing TrxR was also inhibited by
auranofin to ensure that if TrxR had a role there would be a decrease in selenoproteins as
demonstrated by the 75Se radiolabeling. It was also shown that treatment of A549 cells
with 3 µM auranofin would inhibit the existing TrxR in A549 cells (Table 2). The
targeted siRNA experiments strongly suggest that TrxR is probably not involved in
selenoprotein synthesis. It then becomes important to discuss the possible mechanism of
the phenotypes seen with the three inhibitors of TrxR.
The three inhibitors of TrxR all exhibited the same phenotype of decreasing
selenium incorporation into selenoproteins.

Instead of TrxR having a part in

selenoprotein synthesis, these compounds are likely acting as an inhibitor of selenium
metabolism as well as inhibiting TrxR. There has been evidence for arsenite to bind
glutathione and selenium, creating a glutathiolated selenium arsenic compound (Gailer,
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George et al. 2002). This metabolic inhibition could be also occurring with ATO and
auranofin. If these inhibitors of TrxR are binding free selenide in the cell, this could
reduce the amount of selenide available to selenophosphate synthetase 2 (SPS2), which in
turn would reduce the amount of selenium for selenoprotein synthesis.
In the case of ATO, the inhibition of selenium metabolism also gives insight to
the possible mechanism of this drug. It has been traditionally thought that ATO worked
by inducing differentiation of malignant promyelocytes through inactivation of the
promyelocytic leukemia-retinoic acid receptor α (PML-RARα) (Zhang, Westervelt et al.
2000). However, recently it was found that ATO was an inhibitor of TrxR (Lu, Chew et
al. 2007). From the data in this study, inhibiting the cell’s ability to produce new
selenoproteins could also be contributing to the chemotherapeutic effects of ATO.
Auranofin likely binds to the selenocysteine in TrxR, which is near the end of the
C-terminus of the protein. It is possible that auranofin binds selenols in general, and that
the location of the selenocysteine in TrxR is more easily bound to than other
selenoproteins. In addition, TrxR is also one of the most abundant selenoproteins.
Auranofin as an inhibitor of selenium metabolism may also shed light onto the
mechanism on which it works as a treatment for rheumatoid arthritis. The mechanism for
action of auranofin is still not understood. This data provides evidence that a decrease in
selenium metabolism could be partially responsible for the effectiveness of this drug.
There have also been cell culture studies looking at the potential of auranofin as a
cancer therapy. In one such study, it was found that auranofin induced apoptosis in
ciplatin resistant ovarian cancer cells, and caused the release of cytochrome c (Marzano,
Gandin et al. 2007). Auranofin also induced apoptosis in acute promyelocytic leukemia
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cells, the type of cancer that ATO is used to treat, when combined with retinoic acid
(Kim, Jin et al. 2004). Given this and the data presented here that auranofin reduces
selenium incorporation into selenoproteins at a sub-toxic level, there is a chance that it
could be useful in cancer therapy, particularly in cancers that require high levels of
selenium due to increased expression of TrxR.
All three of the compounds tested in this study are inhibitors of TrxR. It is known
that deficiency of TrxR1 by stable transfections of siRNA constructs causes a reversal of
a tumorgenic phenotype to normal in mouse lung carcinoma cells and in mice (Yoo, Xu
et al. 2006). It is not yet known that a decrease in selenoprotein synthesis would exert the
same effect. It has been demonstrated here that these inhibitors of TrxR, also inhibit
selenium metabolism, but likely not through inhibition of TrxR. From the siRNA studies,
it was shown that TrxR is not involved in selenoprotein synthesis. The decrease of
selenium incorporation into selenoproteins is likely due to a decrease in available in the
form of selenide. This decrease in selenoprotein synthesis could be key in understanding
how these compounds work against cancer cells. Further studies to assess the chemical
reactivity of selenide with ATO and auranofin should be carried out to confirm this
hypothesis.
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CHAPTER FIVE: RESULTS AND DISCUSSION - MONOMEHTYLARSONOUS
ACID (III) STIMULATES CYTOSOLIC THIOREDOXIN REDUCTASE IN A
NRF2-DEPENDENT MANNER

Overview
Arsenic exposure is a worldwide public health concern. Mammals metabolize
arsenic in the liver by a series of methylation reactions. One of these metabolites is
MMAIII. MMAIII has been shown to be the most cytotoxic of the trivalent arsenicals in
cell culture (Petrick, Ayala-Fierro et al. 2000). It has also been shown to cause lipid
peroxidation, protein carbonylation, and oxidative DNA damage in cell culture studies
(Wang, Jan et al. 2007). MMAIII exposure has induced hyperproliferation, anchorageindependent growth, and tumorigenicity in an immortalized human urothelial cell line
(Bredfeldt, Jagadish et al. 2006).
classified as a carcinogen.

This recent study has suggested that MMAIII be

The mechanism remains undetermined on how these

carcinogenic phenotypes arise with exposure to MMAIII.
The selenoprotein TrxR is regulated by an antioxidant response element in its
promoter sequence (Rundlof, Carlsten et al. 2001). This is under the control of the
Nrf2/Keap1 system. The transcription factor Nrf2 is usually bound to the protein Keap1
(Itoh, Wakabayashi et al. 1999). Keap1 contains redox reactive cysteines and is able to
sense changes in the cellular redox environment. When the cell undergoes oxidative
stress Nrf2 is released from Keap1 and translocates to the nucleus, and activates ARE
containing genes. These genes are part of the cell’s defense against oxidants. Different
compounds can induce the Nrf2/Keap1 response. It was found that sulforaphane induced
TrxR through this system (Hintze, Wald et al. 2003).

55

TrxR is also expressed in higher levels in many tumors including breast, thyroid,
prostate, liver, malignant melanoma, and colorectal (Berggren, Gallegos et al. 1996;
Gladyshev, Factor et al. 1998).

Reduced thioredoxin, TrxR’s primary substrate, is

involved in DNA synthesis, and integral to cell proliferation (Laurent, Moore et al. 1964).
Recently it has been suggested that TrxR not only be a marker for cancer, but a potential
target for cancer therapy (Arner and Holmgren 2006).

A comparison of the cytotoxicity of MMAIII between A549 and WI-38 cells
As with the previous studies, cytotoxicity, in this case the cytoxicity of MMAIII,
was first determined in A549 and WI-38 cells. A549 cells are an alveolar type II
epithelial-like adenocarcinoma line.

Contrastingly, WI-38 cells are a primary lung

fibroblast, which act accordingly to the Hayflick model and have been used extensively
for studies on cellular senescence (Hayflick and Moorhead 1961; Place, Noonan et al.
2005). Our goal is to determine the effects of MMAIII on selenoproteins in a transformed
and primary cell line.
A549 cells were found to be more resistant to MMAIII than WI-38 cells (Figure 14
A and B). At approximately 12 µM treatment in A549 cells there is a 50% reduction in
cell viability (Figure 14 A). In WI-38 cells treated with 6 µM MMAIII there is a 50%
decrease in cell viability (Figure 14 B). Thus, MMAIII is much more cytotoxic in the
primary cells. This could be due to a variety of reasons. One could be that uptake of
MMAIII is not as efficient in A549 cells. Another could be that during the transformation
of A549 cells were altered that enable them to be more resistant to MMAIII.
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A

B

Figure 14. MMAIII is more cytotoxic in WI-38 cells, than in A549 cells
A549 (A) and WI-38 (B) cells were cultured in the appropriate medium (different for
each cell type) and treated with MMAIII for 24 hours before adding MTT dye. After
solubolize the dye, the plates were analyzed after 24 hours at 570 nm.
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Selenium incorporation into TrxR increases in WI-38 cells with addition of MMAIII
To determine the effects of MMAIII on selenium metabolism, both cell types were
exposed to MMAIII and labeled with 75Se (selenite) radioisotope. Treatment with MMAIII
resulted in no change in selenium incorporation into selenoproteins in A549 cells as
determined by radiolabeling with

75

Se (Figure 15 A).

Even at 6 µM, the highest

concentration tested, there is no change in selenoprotein synthesis. The levels of MMAIII
tested in both cell types were sub-toxic. In a previous related study, it was found that
MMAIII

did

not

effect

general

protein

synthesis

as

determined

by

35

S

(cysteine/methionine) radiolabeling (Ganyc, Talbot et al. 2007).
However, exposure to MMAIII in WI-38 cells caused an increase in what is
believed to be TrxR (the band labeled I) synthesis (Figure 15 B). To our knowledge, no
prior 75Se labeling studies have been conducted in this cell line, and so the selenoproteins
have not been identified by where they would appear and with what intensities by
phosphorimage analysis. This increase was seen at treatment with 1 and 2 µM MMAIII.
While TrxR was increasing, selenium incorporation into smaller selenoproteins, possibly
cellular glutathione peroxidase (cGPx), was decreasing (Figure 15 B). Further analysis of
the densitometry of the band possibly representing TrxR (I) revealed a two-fold increase
at these concentrations compared to control (Figure 15 C). The densitometry analysis of
the smaller selenoprotein band II showed a sharp decease with increasing exposure to
MMAIII. This contrast in an increase in TrxR and decrease in smaller selenoproteins
could be a result of MMAIII affecting the selenoprotein hierarchy.
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C

Figure 15. TrxR increases synthesis with exposure to MMAIII, at the expense of
smaller selenoproteins
A549 cells (A) were treated with 0,2, or 6 µM MMAIII, and WI-38 cells (B) with 0, 0.2,
or 2 µM MMAIII in triplicate. Immediately following exposure to MMAIII cells were
labeled with

75

Se (selenite) and incubated for 24 hours before harvesting. 25 µg of
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protein was separated by SDS-PAGE (15%).

Selenoproteins were visualized by

phosphorimage analysis. TrxR was identified by using a standard protein marker (not
shown) in A549 cells. Band intensity of WI-38 gel (C) was determined by densitometry
analysis with ImageQuant software.
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MMAIII increases TrxR1 mRNA levels in WI-38 cells
After examining the effect of MMAIII on selenium incorporation into
selenoproteins, the next step was to begin to identify the mechanism behind the observed
phenotypes. This included looking at mRNA expression, activity, and regulation of
TrxR. Expression levels of the gene encoding TrxR1were monitored by real time RTPCR. In A549 cells cultured with 0, 2, or 6 µM MMAIII there was no significant change
in TrxR1 mRNA levels (Figure 16 A). This correlates with the radiolabeling by 75Se, in
which treatment with MMAIII did not effect TrxR levels.
In contrast to the A549 cells, treatment with 2 µM MMAIII did cause a significant
increase in mRNA expression levels of TrxR1 (*, p<0.05) (Figure 16 B). However,
treatment with 0.2 µM did not elicit the same effect. This also shows a relationship to the
radiolabeling data in which 2 µM MMAIII increased what is believed to be TrxR
synthesis by two-fold.
Treatment of WI-38 cells with MMAIII also caused mRNA levels of cGPx to
decrease (Figure 16 C). At exposure to 2 µM MMAIII there was a significant decrease.
This also correlates with the labeling data in this cell line. There was a decrease with
exposure to MMAIII in selenium incorporation into smaller selenoproteins, including a
band we believed to be cGPx (Figure 15 B). The RT-PCR data suggests that this band is
more than likely cGPx. cGPx levels are not assessable in A549 cells due to the extremely
low amount that they produce (Avissar, Finkelstein et al. 1996).
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A

B
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C

Figure 16. Treatment with MMAIII in WI-38 cells leads to a significant increase in
mRNA levels encoding TrxR1
A549 (A) and WI-38 (B and C) cells were cultured with 0, 2, or 6 µM (A549) or 0, 0.2,
or 2 µM (WI-38) MMAIII for 24 hours. Cells were harvested and RNA isolated for realtime RT-PCR analysis. β-actin was used as an internal standard. Relative expression
(fold) plotted is a representative experiment with cultures grown in triplicate for A549
cells and duplicate for WI-38 cells. (A) and (B) are graphs representing expression of
mRNA levels of TrxR1, and (C) is expression of mRNA levels of cGPx. Each culture
was analyzed in triplicate.

Error bars represent standard deviation.

significance was determined by Student’s t-test.
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Statistical

MMAIII inhibits activity of TrxR in A549 cells and varies activity in WI-38 cells
MMAIII is a known potent inhibitor of TrxR in vitro (Lin, Cullen et al. 1999).
Both cell lines were cultured with increasing concentrations of MMAIII for 48 hours
before harvesting and determining TrxR activity by DTNB assay (Smith and Levander
2002). In A549 cells TrxR was inhibited at 6 µM MMAIII (Table 3). It should be noted
that even though MMAIII does not effect selenoprotein synthesis or mRNA expression of
TrxR1 in this cell type, it does inhibit the enzyme.
Slightly different results were obtained in WI-38 cells exposed to MMAIII. At
treatment with 0.2 µM MMAIII the activity of TrxR increases above that of control (Table
3). When cultured with 2 µM MMAIII, TrxR activity decreases compared to control, but
some residual activity remains. When A549 cells were exposed to 2 µM MMAIII there
was a slight decrease in activity, but probably not enough of a decrease to be considered
significant due to the error.

If WI-38 cells were treated with 6 µM MMAIII, the

concentration that inhibited the enzyme in A549 cells, it would be too toxic to the cells to
be able to properly analyze the data. At that concentration of MMAIII, rounding and cell
death was observed with WI-38 cells (data not shown).
Given that MMAIII inhibits TrxR in A549, but not necessarily WI-38 cells, it
becomes necessary to examine the regulation of TrxR1 to try to pinpoint the mechanism
by which MMAIII is increasing synthesis of TrxR1 mRNA in WI-38 cells.
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Table 3. MMAIII significantly affects TrxR activity in both A549 and WI-38 cells
A549 cells were cultured with 0, 2, or 6 µM MMAIII, and WI-38 cells with 0, 0.2, or 2
µM MMAIII for 48 hours to allow for complete inhibition of TrxR before harvesting.
Activity assays based on the reduction of DTNB were performed to determine the
activity of TrxR. Cell culture treatment groups were grown in duplicate and analyzed in
duplicate. These are representative experiments of independent triplicate experiments for
each cell type.
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MMAIII treatment results in activation of transcription of the TrxR1 promoter
The TrxR promoter is regulated by the ARE (Rundlof, Carlsten et al. 2001). To
test if MMAIII induces TrxR through the ARE, promoter fusion luciferase constructs were
transfected into both cell lines. This included a wild type TrxR1 promoter containing the
ARE, and another construct with a mutated (Mut) ARE in the TrxR1 promoter region. If
MMAIII exerts any effects on the ARE of TrxR1, the same effects should not be seen in
the mutated construct.
A549 cells, with the exception of MMAIII inhibiting TrxR, have shown no
changes in selenoprotein synthesis, and mRNA expression levels of TrxR1 in response to
MMAIII exposure. With the transfection of the TrxR1 promoter fusion constructs there
was no change in luciferase activity as compared to control when exposed to either 2 or 6
µM MMAIII (Figure 17 A).

As expected the mutated ARE promoter construct’s

luciferase activity also did not change.
Unlike the A549 cells, the transfected WI-38 cells with the wild-type TrxR1 ARE
promoter fusion construct displayed increased luciferase activity with exposure to 2 µM
MMAIII (*, p< 0.05) (Figure 17 B). There was a slight increase with treatment with 0.2
µM MMAIII, but not enough to be considered significant. If MMAIII is truly stimulating
TrxR1 production through the ARE element and thus the Nrf2-Keap1 response, then the
mutated ARE construct should yield no change in luciferase activity with MMAIII
exposure. Transfected WI-38 cells with the mutant construct did indeed behave this way.
At exposure to 0.2 and 2 µM MMAIII there was no significant change in luciferase
activity. This indicates that MMAIII is causing an Nrf2 response through the ARE in
TrxR1. TrxR1 is not the only protein that contains an ARE element in its promoter. The

66

next logical step was to confirm that exposure to MMAIII stimulates expression of
another protein whose synthesis is regulated at the transcriptional level by the
Nrf2/Keap1 system, and contains an ARE in its promoter sequence.
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A

B

Figure 17. Treatment with MMAIII in WI-38 cells induces TrxR expression through
the ARE
Both cell types were transfected with TrxR1 or mutant TrxR1 (Mut) promoter fusion
constructs. A549 cells (A) were treated with 0, 2, or 6 µM MMAIII, and WI-38 cells (B)
68

with 0, 0.2, or 2 µM MMAIII in triplicate for 24 hours before assaying for luciferase
activity. Plotted luciferase activity (fold) is based on the ratio of luciferase activity to that
of renilla, with error as standard deviation. Student’s t-tests were performed to determine
significance. These are representative experiments of multiple independent experiments
conducted in triplicate for each treatment group.
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Induction of quinone reductase in WI-38 cells by MMAIII
The gene encoding for quinone reductase contains an ARE element in the
promoter region, and is not known to be involved in selenium metabolism (Hintze, Wald
et al. 2003). A549 and WI-38 cells were transfected with a rat quinone reductase (QR)
promoter fusion construct that contained the ARE.

If MMAIII is regulating TrxR1

through the ARE, then the results should be the same as the transfections with wild-type
TrxR1 in both cell types with exposure to MMAIII.
In A549 cells carrying the QR promoter fusion construct and exposed to MMAIII
for 24 hours there was no change in luciferase activity between treatment groups (Figure
18 A). These results are similar to those obtained for the wild-type TrxR1. However, in
WI-38 cells transfected with the QR construct and exposed to varying concentrations of
MMAIII, there was an increase in QR promoter fusion activity with treatment of 2 µM
MMAIII (Figure 18 B).

This was the same concentration that stimulated luciferase

activity in TrxR1 in this cell line. There also was a slight increase in activity with
treatment at 0.2 µM MMAIII, but not enough to be considered significant.
We have thus shown that both TrxR1 and QR are regulated at the transcriptional
level by the Nrf2/Keap1 system with exposure to MMAIII.

This implicates the

mechanism of MMAIII inducing TrxR1 synthesis is through the Nrf2/Keap1 response. To
our knowledge, this is the first demonstration of induction of the Nrf2/Keap1 response to
MMAIII.
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B

Figure 18. Regulation of QR in WI-38 cells by MMAIII
A549 (A) and WI-38 (B) cells were transfected with rat quinone reductase (QR) promoter
fusion constructs and exposed to increasing concentrations of MMAIII for 24 hours before
assaying for luciferase and renilla activities. The relative luciferase activity (fold) is the
ratio of luciferase to renilla activity, with standard deviation as error.
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Statistical

significance was determined by Student’s t-tests. These are representative experiments of
multiple independent experiments for each cell type and were conducted in triplicate.
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CHAPTER SIX: CONCLUSIONS OF MONOMEHTYLARSONOUS ACID (III)
STIMULATES CYTOSOLIC THIOREDOXIN REDUCTASE IN A NRF2DEPENDENT MANNER
MMAIII is a metabolite of arsenic produced during the methylation reactions
carried out to facilitate excretion. It is not found in the natural environment, but is
generated during the excretory pathway of inorganic arsenic. It has been found to be the
most cytotoxic of all arsenicals and could prove to be the most carcinogenic (Petrick,
Ayala-Fierro et al. 2000; Bredfeldt, Jagadish et al. 2006).
It has also been shown that selenium and arsenic interact according to a mutual
sparring effect (Moxon 1938). This means that as the levels of arsenic increase the
amount of available selenium decreases and visa versa.

If someone is exposed to

inorganic arsenic this will result in lower selenium levels in tissues, and could reduce
selenium to the point that it affects selenoprotein synthesis. When selenium levels begin
to be depleted, there is a certain point that the cell will begin to preferentially make some
selenoproteins over others (Low, Grundner-Culemann et al. 2000). This is known as the
selenoprotein hierarchy. TrxR, because of its importance in maintaining the cellular
redox environment is one of the selenoproteins at the top of the hierarchy and will be
expressed under selenium limiting conditions.
When WI-38 cells were exposed to MMAIII TrxR synthesis increased, while
smaller selenoproteins, based on initial analysis to be cGPx, decreased as determined by
radiolabeling with
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Se. This phenotype with MMAIII exposure was also observed in a

previous study with HaCat cells (human keratinocytes) (Ganyc, Talbot et al. 2007), but
the mechanism was not yet elucidated. It should be considered that people who do have
MMAIII in their system as a result of exposure to arsenic, would likely have low selenium
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levels.

Depending on the amount of exposure to arsenic they could be selenium

compromised to a level that is lower than that used in our cell culture studies.
Treatment with MMAIII also led to an increase in TrxR1 mRNA levels in WI-38
cells. This correlates with the radiolabeling data. The decrease in cGPx mRNA levels in
WI-38 cells also correlates with radiolabeling. Under selenium limiting conditions, cGPx
will not be preferentially expressed over TrxR1.
Treatment of A549 cells with MMAIII had no effect on selenoprotein synthesis,
expression levels or regulation. It did however inhibit TrxR activity. The question
becomes what is different about the WI-38 cells from A549. WI-38 cells are a primary
lung fibroblast, while A549 cells were originally isolated from an adenocarcinoma and
are therefore transformed. One obvious difference lies in the regulation of TrxR1 and
other ARE containing genes.

A recent study showed that A549 cells have the

transcription factor Nrf2 constitutively localized in the nucleus (Kweon, Adhami et al.
2006). This suggests that all ARE containing genes are constitutively expressed and are
no longer regulated through the Nrf2/Keap1 system. This explains why addition of
MMAIII did not induce upregulation of either TrxR1 and QR promoter. The WI-38 cells
are not derived from a tumor, and have a wild-type Nrf2/Keap1 system. This was the key
difference between the two cell lines in how MMAIII effects regulation of TrxR1.
It is a novel finding that MMAIII induces TrxR1 through the ARE. This is also
interesting from a carcinogenic standpoint.

Many tumors have TrxR upregulated

(Berggren, Gallegos et al. 1996; Gladyshev, Factor et al. 1998). TrxR has also been
suggested to be potential target for cancer therapy. Since we have demonstrated that
MMAIII induces TrxR1 through the Nrf2/Keap1 response, this may be part of the
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mechanism of how exposure to MMAIII can result in carcinogenesis. By inducing TrxR1
the cell is not only trying to defend itself from the ROS that MMAIII can generate, but
with more TrxR1 more thioredoxin can be reduced. This in turn can lead to increased
cell proliferation, DNA synthesis and resistance to apoptosis. This combination, along
with low selenium status and higher levels of ROS, could indeed be a recipe for
carcinogenesis.
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